Oral Proteins and Peptides Market - Future Growth By Top Players Involved In The Market Like Allergan plc, AstraZeneca plc, Biocon Limited, Chiasma, Inc., Proxima Concepts Limited (Diabetology Ltd.) and more

The worldwide oral proteins and peptides market is estimated at $ 643 million in 2016 and is expected to reach $ 82.23 billion by 2023 and grow at a CAGR of 11.7% from 2022 to 2028.

Therapeutic proteins and peptides are an important class of drugs that provide services to patients in need of new treatments. Approved oral protein and peptide drugs are known to treat a variety of clinical signs including diabetes, gastrointestinal disorders and hormonal disorders.

Key factors driving the growth of the global oral protein and peptide market include increased collaboration efforts among pharmaceutical companies, the spread of chronic diseases, increased elderly population, oral proteins and peptide-based drugs.

However, the high costs associated with drug development and the low bioavailability of these drugs hamper market growth. In contrast, an increase in new indications for oral protein therapeutics, high R & D investment in pharmaceuticals and peptide drugs for oral use, and increased purchasing power in emerging markets are expected to provide manufacturers with a favorable opportunity in this industry.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/378?utm_source=sy-Openpr

The report provides extensive competitive analysis and profiles of key market players, such as
• Allergan plc
• AstraZeneca plc
• Biocon Limited
• Chiasma Inc.
• Proxima Concepts Limited (Diabetology Ltd.)
• Generex Biotechnology Corp.
• Novo Nordisk A/S
• Synergy Pharmaceuticals Inc.
• Tarsa Therapeutics Inc.

Other players (profiles not included in the report) in the value chain analysis include Sanofi S.A., F. Hoffmann-La Roche AG, Synthetic Biologics, Inc., Hovione Limited, and Novartis International AG.

The gastric & digestive disorders application generated the highest revenue in 2016, and is anticipated to continue this trend in the future. This is attributed to the approval and high adoption of oral proteins and peptide drugsLINZESS (Allergan, Inc.) and TRULANCE (Synergy Pharmaceuticals, Inc.). The diabetes application is anticipated to grow at the highest CAGR of 13.4% from 2022 to 2028.

The U.S. held the highest market share in 2016, owing to high prevalence rate of chronic diseases, rise in adoption of these drugs, and increase in awareness about oral protein and peptide therapeutics. The rest of the world is expected to grow owing to rapid industrialization, increase in disposable income, and upsurge in government initiatives to modernize healthcare infrastructure.

Buy Now (Data Pack Available with Discounted Price): @ https://www.alliedmarketresearch.com/checkout/674908?utm_source=sy-Openpr

Key Findings of the Oral Proteins And Peptides Market:
• The insulin drug type segment is anticipated to grow at the highest CAGR from 2022 to 2028
• The gastric & digestive disorder application segment is anticipated to occupy the largest share in the oral proteins and peptides market
• The diabetes segment is expected to witness the highest growth rate during the forecast period
• The U.S. dominated the oral proteins and peptides market, and is projected to grow at a CAGR of 11.7%.

Access Full Summery @ https://www.alliedmarketresearch.com/oral-proteins-peptides-market?utm_source=sy-Openpr

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This release was published on openPR.